{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:12Z","timestamp":1790741592964,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2014_A265"],"award-info":[{"award-number":["2014_A265"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008426","name":"Friedrich-Baur-Stiftung","doi-asserted-by":"publisher","award":["61\/17"],"award-info":[{"award-number":["61\/17"]}],"id":[{"id":"10.13039\/501100008426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early diagnosis of CNS lymphoma (CNSL) is essential for successful therapy of this rapidly progressing brain tumor. However, in patients presenting with focal brain lesions, fast and reliable diagnosis of PCNSL remains a challenge. A proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) are important factors in the pathophysiology, diagnosis, and prognosis of systemic B cell malignancies. However, their utility as biomarkers for the diagnosis of CNSL and their effects on CNSL cells remain unclear.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective study, we analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. Additionally, we serially measured their levels during chemotherapy and relapse. Furthermore, we analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CSF levels of APRIL and BAFF reliably differentiated CNSL from other focal brain lesions (including primary and metastatic brain tumors, autoimmune-inflammatory lesions, and neuroinfectious lesions) with a specificity of 93.7% (APRIL, BAFF) and a sensitivity of 62.3% (APRIL) and 47.1% (BAFF). Serial CSF analysis of CNSL patients during chemotherapy and relapse demonstrates a close correlation of APRIL CSF levels and the course of this disease. In vitro, APRIL and BAFF showed anti-apoptotic effects during MTX treatment and mediated chemotaxis of malignant B cells.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study extends the spectrum of valuable diagnostic biomarkers in CNSL. In patients with focal brain lesions, measurement of APRIL in CSF could help accelerating the diagnosis of CNSL. Moreover, our results highlight an important role of APRIL and BAFF in the pathophysiology of CNSL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-019-0796-4","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:15:03Z","timestamp":1571138103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["APRIL and BAFF: novel biomarkers for central nervous system lymphoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Matthias","family":"Mulazzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Borchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Angele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Koedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-0927","authenticated-orcid":false,"given":"Louisa","family":"von Baumgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"issue":"2","key":"796_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/hon.2087","volume":"32","author":"M Deckert","year":"2014","unstructured":"Deckert M, Brunn A, Montesinos-Rongen M, Terreni MR, Ponzoni M. Primary lymphoma of the central nervous system--a diagnostic challenge. Hematol Oncol. 2014;32(2):57\u201367.","journal-title":"Hematol Oncol"},{"issue":"12","key":"796_CR2","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00277-011-1225-0","volume":"90","author":"T Lim","year":"2011","unstructured":"Lim T, et al. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann Hematol. 2011;90(12):1391\u20138.","journal-title":"Ann Hematol"},{"issue":"12","key":"796_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/leu.2011.169","volume":"25","author":"M Deckert","year":"2011","unstructured":"Deckert M, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797\u2013807.","journal-title":"Leukemia"},{"issue":"14","key":"796_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1212\/01.wnl.0000326958.52546.f5","volume":"71","author":"L Fischer","year":"2008","unstructured":"Fischer L, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008;71(14):1102\u20138.","journal-title":"Neurology"},{"issue":"6","key":"796_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"796_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00701-007-1473-x","volume":"150","author":"R Dammers","year":"2008","unstructured":"Dammers R, et al. Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir. 2008;150(1):23\u20139.","journal-title":"Acta Neurochir"},{"issue":"5","key":"796_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.21366","volume":"63","author":"AB Porter","year":"2008","unstructured":"Porter AB, et al. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol. 2008;63(5):662\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"796_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1200\/JCO.1999.17.2.554","volume":"17","author":"A Antinori","year":"1999","unstructured":"Antinori A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol. 1999;17(2):554\u201360.","journal-title":"J Clin Oncol"},{"issue":"3","key":"796_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/neuonc\/nor203","volume":"14","author":"T Sasayama","year":"2012","unstructured":"Sasayama T, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro-oncology. 2012;14(3):368\u201380.","journal-title":"Neuro-oncology"},{"issue":"1","key":"796_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-014-1622-z","volume":"121","author":"Y Sasagawa","year":"2015","unstructured":"Sasagawa Y, Akai T, Tachibana O, Iizuka H. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neuro-Oncol. 2015;121(1):177\u201383.","journal-title":"J Neuro-Oncol"},{"issue":"23","key":"796_CR11","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","volume":"121","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740\u20138.","journal-title":"Blood"},{"key":"796_CR12","doi-asserted-by":"publisher","first-page":"38671","DOI":"10.1038\/srep38671","volume":"6","author":"Y Song","year":"2016","unstructured":"Song Y, et al. Cerebrospinal fluid IL-10 and IL-10\/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma. Sci Rep. 2016;6:38671.","journal-title":"Sci Rep"},{"issue":"11","key":"796_CR13","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/neuonc\/nov092","volume":"17","author":"A Viaccoz","year":"2015","unstructured":"Viaccoz A, et al. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol. 2015;17(11):1497\u2013503.","journal-title":"Neuro Oncol"},{"issue":"6","key":"796_CR14","first-page":"631","volume":"63","author":"C Caudie","year":"2005","unstructured":"Caudie C, et al. CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin. Ann Biol Clin (Paris). 2005;63(6):631\u20137.","journal-title":"Ann Biol Clin (Paris)"},{"issue":"1","key":"796_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11060-016-2162-5","volume":"129","author":"F Strehlow","year":"2016","unstructured":"Strehlow F, et al. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neuro-Oncol. 2016;129(1):165\u201371.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"796_CR16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood.V87.5.1985.1985","volume":"87","author":"MJ Kersten","year":"1996","unstructured":"Kersten MJ, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996;87(5):1985\u20139.","journal-title":"Blood"},{"issue":"11","key":"796_CR17","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","volume":"117","author":"A Baraniskin","year":"2011","unstructured":"Baraniskin A, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140\u20136.","journal-title":"Blood"},{"issue":"10","key":"796_CR18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/neuonc\/nor107","volume":"13","author":"L Fischer","year":"2011","unstructured":"Fischer L, et al. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro-oncology. 2011;13(10):1090\u20138.","journal-title":"Neuro-oncology"},{"issue":"4","key":"796_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/modpathol.2009.10","volume":"22","author":"JL Robertus","year":"2009","unstructured":"Robertus JL, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol. 2009;22(4):547\u201355.","journal-title":"Mod Pathol"},{"issue":"10","key":"796_CR20","first-page":"2048","volume":"6","author":"J Zheng","year":"2013","unstructured":"Zheng J, et al. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas. Int J Clin Exp Pathol. 2013;6(10):2048\u201355.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"796_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/cpr.12243","volume":"49","author":"X Yu","year":"2016","unstructured":"Yu X, Li Z, Shen J, Chan MT, Wu WK. Role of microRNAs in primary central nervous system lymphomas. Cell Prolif. 2016;49(2):147\u201353.","journal-title":"Cell Prolif"},{"issue":"1","key":"796_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","volume":"7","author":"V Rimelen","year":"2019","unstructured":"Rimelen V, et al. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun. 2019;7(1):43.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"796_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","volume":"244","author":"RC Rickert","year":"2011","unstructured":"Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244(1):115\u201333.","journal-title":"Immunol Rev"},{"issue":"5","key":"796_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","volume":"18","author":"SG Tangye","year":"2006","unstructured":"Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol. 2006;18(5):305\u201317.","journal-title":"Semin Immunol"},{"issue":"3","key":"796_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.coi.2007.04.008","volume":"19","author":"F Mackay","year":"2007","unstructured":"Mackay F, Silveira PA, Brink R. B cells and the BAFF\/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol. 2007;19(3):327\u201336.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"796_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20041674","volume":"201","author":"M Krumbholz","year":"2005","unstructured":"Krumbholz M, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195\u2013200.","journal-title":"J Exp Med"},{"issue":"8","key":"796_CR27","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004;104(8):2247\u201353.","journal-title":"Blood"},{"issue":"3","key":"796_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1600-0609.2008.01099.x","volume":"81","author":"SJ Kim","year":"2008","unstructured":"Kim SJ, et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol. 2008;81(3):177\u201384.","journal-title":"Eur J Haematol"},{"issue":"1","key":"796_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2006-02-001800","volume":"109","author":"J Schwaller","year":"2007","unstructured":"Schwaller J, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood. 2007;109(1):331\u20138.","journal-title":"Blood"},{"issue":"12","key":"796_CR30","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/acn3.668","volume":"5","author":"H Mizutani","year":"2018","unstructured":"Mizutani H, et al. CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers. Ann Clin Transl Neurol. 2018;5(12):1611\u20136.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"796_CR31","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/neuonc\/nox097","volume":"19","author":"FS Thaler","year":"2017","unstructured":"Thaler FS, et al. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. Neuro Oncol. 2017;19(12):1618\u201327.","journal-title":"Neuro Oncol"},{"issue":"1","key":"796_CR32","doi-asserted-by":"publisher","DOI":"10.4081\/ni.2013.e4","volume":"5","author":"T Birnbaum","year":"2013","unstructured":"Birnbaum T, Langer S, Roeber S, von Baumgarten L, Straube A. Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma. Neurol Int. 2013;5(1):e4.","journal-title":"Neurol Int"},{"issue":"1","key":"796_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-010-0233-6","volume":"101","author":"D Muta","year":"2011","unstructured":"Muta D, et al. Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neuro-Oncol. 2011;101(1):33\u20139.","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"796_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bjh.15410","volume":"182","author":"A van Westrhenen","year":"2018","unstructured":"van Westrhenen A, et al. Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. Br J Haematol. 2018;182(3):384\u2013403.","journal-title":"Br J Haematol"},{"issue":"2","key":"796_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11060-012-0908-2","volume":"109","author":"A Baraniskin","year":"2012","unstructured":"Baraniskin A, et al. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neuro-Oncol. 2012;109(2):239\u201344.","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"796_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/neuonc\/nov144","volume":"18","author":"A Baraniskin","year":"2016","unstructured":"Baraniskin A, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro-oncology. 2016;18(3):361\u20137.","journal-title":"Neuro-oncology"},{"issue":"3","key":"796_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ejca.2014.10.028","volume":"51","author":"P Roth","year":"2015","unstructured":"Roth P, et al. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Eur J Cancer. 2015;51(3):382\u201390.","journal-title":"Eur J Cancer"},{"issue":"2","key":"796_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10072-013-1491-9","volume":"35","author":"X Mao","year":"2014","unstructured":"Mao X, Sun Y, Tang J. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci. 2014;35(2):233\u20138.","journal-title":"Neurol Sci"},{"issue":"1","key":"796_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12032-014-0351-7","volume":"32","author":"HT Zhao","year":"2015","unstructured":"Zhao HT, Chen J, Shi SB, Tian J, Tao RJ. Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma. Med Oncol. 2015;32(1):351.","journal-title":"Med Oncol"},{"issue":"29","key":"796_CR40","doi-asserted-by":"publisher","first-page":"48157","DOI":"10.18632\/oncotarget.18325","volume":"8","author":"M Fontanilles","year":"2017","unstructured":"Fontanilles M, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017;8(29):48157\u201368.","journal-title":"Oncotarget"},{"issue":"1","key":"796_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/cas.13450","volume":"109","author":"K Hattori","year":"2018","unstructured":"Hattori K, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018;109(1):225\u201330.","journal-title":"Cancer Sci"},{"issue":"5","key":"796_CR42","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.18632\/oncotarget.14008","volume":"8","author":"AK Cani","year":"2017","unstructured":"Cani AK, et al. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Oncotarget. 2017;8(5):7989\u201398.","journal-title":"Oncotarget"},{"key":"796_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","volume":"127","author":"LS Hiemcke-Jiwa","year":"2018","unstructured":"Hiemcke-Jiwa LS, et al. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities. Crit Rev Oncol Hematol. 2018;127:56\u201365.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"796_CR44","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","volume":"121","author":"M Varettoni","year":"2013","unstructured":"Varettoni M, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522\u20138.","journal-title":"Blood"},{"issue":"1\u20132","key":"796_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jns.2015.03.036","volume":"352","author":"A Kimura","year":"2015","unstructured":"Kimura A, Yoshikura N, Koumura A, Hayashi Y, Inuzuka T. B-cell-activating factor belonging to the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) levels in cerebrospinal fluid of patients with meningoencephalitis. J Neurol Sci. 2015;352(1\u20132):79\u201383.","journal-title":"J Neurol Sci"},{"issue":"2","key":"796_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ajh.21328","volume":"84","author":"SM Ansell","year":"2009","unstructured":"Ansell SM, et al. Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Am J Hematol. 2009;84(2):71\u20133.","journal-title":"Am J Hematol"},{"issue":"4","key":"796_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.autrev.2009.08.001","volume":"9","author":"GJ Tobon","year":"2010","unstructured":"Tobon GJ, Pers JO, Youinou P, Saraux A. B cell-targeted therapies in Sjogren\u2019s syndrome. Autoimmun Rev. 2010;9(4):224\u20138.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"796_CR48","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","volume":"66","author":"F Lavie","year":"2007","unstructured":"Lavie F, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66(5):700\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"796_CR49","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458511398887","volume":"17","author":"S Ragheb","year":"2011","unstructured":"Ragheb S, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011;17(7):819\u201329.","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"796_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jneuroim.2010.01.011","volume":"220","author":"F Piazza","year":"2010","unstructured":"Piazza F, et al. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J Neuroimmunol. 2010;220(1\u20132):104\u20137.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"796_CR51","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","volume":"32","author":"H Wang","year":"2012","unstructured":"Wang H, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32(5):1007\u201311.","journal-title":"J Clin Immunol"},{"issue":"11","key":"796_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","volume":"8","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613\u201323.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"796_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070924","volume":"8","author":"S Tada","year":"2013","unstructured":"Tada S, et al. BAFF controls neural cell survival through BAFF receptor. PLoS One. 2013;8(7):e70924.","journal-title":"PLoS One"},{"issue":"3\u20134","key":"796_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","volume":"14","author":"F Mackay","year":"2003","unstructured":"Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev. 2003;14(3\u20134):311\u201324.","journal-title":"Cytokine Growth Factor Rev"},{"key":"796_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2407-9-83","volume":"9","author":"J Moreaux","year":"2009","unstructured":"Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer. 2009;9:83.","journal-title":"BMC Cancer"},{"issue":"12","key":"796_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083250","volume":"8","author":"V Pelekanou","year":"2013","unstructured":"Pelekanou V, et al. BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis. PLoS One. 2013;8(12):e83250.","journal-title":"PLoS One"},{"issue":"17","key":"796_CR57","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1038\/sj.onc.1207350","volume":"23","author":"F Deshayes","year":"2004","unstructured":"Deshayes F, et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene. 2004;23(17):3005\u201312.","journal-title":"Oncogene"},{"issue":"7","key":"796_CR58","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1084\/jem.192.7.953","volume":"192","author":"RK Do","year":"2000","unstructured":"Do RK, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192(7):953\u201364.","journal-title":"J Exp Med"},{"issue":"8","key":"796_CR59","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2002-02-0558","volume":"100","author":"AJ Novak","year":"2002","unstructured":"Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002;100(8):2973\u20139.","journal-title":"Blood"},{"key":"796_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231\u201364.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"796_CR61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1084\/jem.192.1.137","volume":"192","author":"XZ Xia","year":"2000","unstructured":"Xia XZ, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med. 2000;192(1):137\u201343.","journal-title":"J Exp Med"},{"issue":"19","key":"796_CR62","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1182\/blood-2008-10-183467","volume":"113","author":"L Fu","year":"2009","unstructured":"Fu L, et al. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB\/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood. 2009;113(19):4627\u201336.","journal-title":"Blood"},{"issue":"2","key":"796_CR63","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","volume":"103","author":"C Kern","year":"2004","unstructured":"Kern C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103(2):679\u201388.","journal-title":"Blood"},{"issue":"5","key":"796_CR64","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.4049\/jimmunol.172.5.3268","volume":"172","author":"B He","year":"2004","unstructured":"He B, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF\/BLyS and APRIL. J Immunol. 2004;172(5):3268\u201379.","journal-title":"J Immunol"},{"issue":"1","key":"796_CR65","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/leu.2008.266","volume":"23","author":"T Lwin","year":"2009","unstructured":"Lwin T, et al. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin\u2019s B lymphoma cells from apoptosis. Leukemia. 2009;23(1):170\u20137.","journal-title":"Leukemia"},{"issue":"2","key":"796_CR66","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4049\/jimmunol.1402070","volume":"194","author":"FS Hoffmann","year":"2015","unstructured":"Hoffmann FS, et al. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol. 2015;194(2):542\u201352.","journal-title":"J Immunol"},{"key":"796_CR67","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, et al. gamma-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:7333.","journal-title":"Nat Commun"},{"issue":"5","key":"796_CR68","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2007-03-081232","volume":"111","author":"G Badr","year":"2008","unstructured":"Badr G, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood. 2008;111(5):2744\u201354.","journal-title":"Blood"},{"issue":"6","key":"796_CR69","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365\u201373.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:23:37Z","timestamp":1602631417000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0796-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local ethics committee (LMU Munich, Germany) according to the Declaration of Helsinki (registration number 174-11).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}